Last reviewed · How we verify
Tranexamic acid intravenous administration
Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.
Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability. Used for Reduction of blood loss in surgical procedures, Treatment of excessive bleeding in hemophilia and other bleeding disorders, Prevention and treatment of hemorrhage in trauma patients.
At a glance
| Generic name | Tranexamic acid intravenous administration |
|---|---|
| Also known as | intravenous saline administration |
| Sponsor | Dr. Lutfi Kirdar Kartal Training and Research Hospital |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits the binding of plasminogen and plasmin to fibrin. By blocking fibrinolysis, it stabilizes formed blood clots and reduces excessive bleeding. It is commonly used to reduce blood loss in surgical procedures and manage bleeding disorders.
Approved indications
- Reduction of blood loss in surgical procedures
- Treatment of excessive bleeding in hemophilia and other bleeding disorders
- Prevention and treatment of hemorrhage in trauma patients
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Nausea and vomiting
- Diarrhea
- Headache
- Visual disturbances
Key clinical trials
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH (PHASE3)
- Tranexamic Acid for Bleeding Reduction During TURP Surgery (PHASE4)
- One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures (NA)
- Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage (PHASE4)
- Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery (EARLY_PHASE1)
- The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: